Digital Twin Patient Builderv0.1.0

Oncologists use the digital twin to simulate chemotherapy drug responses based on patient genotype and tumor imaging. The system predicts efficacy and toxicity for multiple dose regimens, enabling tailored treatment plans.

Pharmaceutical companies simulate patient cohorts in silico to test drug efficacy and safety before human trials. This reduces costs and accelerates candidate screening by identifying optimal doses and high-risk populations.

Hospitals integrate patient genomic and clinical data to predict adverse drug reactions before prescribing. The digital twin evaluates hepatotoxicity and neutropenia risks, flagging unsafe medications for individual patients.

For patients with comorbidities like hypertension and diabetes, the twin simulates pharmacokinetics across dose ranges. Clinicians receive optimal dose recommendations balancing efficacy and side effect risks over a simulated 30-day period.

Pediatric pharmacologists use age-adjusted physiological models to extrapolate adult drug data to children. The twin simulates clearance and volume distribution differences, informing safe pediatric dosing guidelines.

Pharmaceutical companies pay a monthly or per-simulation fee to use the digital twin platform for virtual clinical trials. Revenue scales with number of drug candidates or simulations run.

Hospitals and health systems license the software for clinical decision support. They deploy it on-premises or via cloud to pre-screen adverse reactions and optimize treatments for enrolled patients.

Aggregate and anonymize simulation data across many patients to generate population-level pharmacogenomic insights. Sell reports or dashboards to biotech firms, insurers, or regulators.